Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors

BACKGROUND: Immune checkpoint inhibitors (ICIs) have become the standard of care for a variety of cancers, including non-small cell lung cancer (NSCLC). In this study, we investigated the frequency of pseudoprogression and hyperprogression in lung cancer patients treated with ICIs in the real world...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Da Hyun, Chung, Chaeuk, Sun, Pureum, Lee, Da Hye, Lee, Song-I, Park, Dongil, Koh, Jeong Suk, Kim, Yoonjoo, Yi, Hyon-Seung, Lee, Jeong Eun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854239/
https://www.ncbi.nlm.nih.gov/pubmed/34278517
http://dx.doi.org/10.1007/s00262-021-03018-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854239/
https://www.ncbi.nlm.nih.gov/pubmed/34278517
http://dx.doi.org/10.1007/s00262-021-03018-y

Ejemplares similares